The US Food and Drug advisory panel has voted for the preliminary approval of Invokana (canagliflozin), Johnson and Johnson’s new type 2 diabetes drug, in a 10 to 5 vote. On the table during the discussion for this potentially innovative drug was the concern that it has significant
Alexza Pharmaceuticals Inc. [NASDAQ: ALXA] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of ADASUVE, being developed for schizophrenia or bipolar I disorder in adults.
Alexza Pharmaceuticals is an emerging pharmaceutical comp
Santarus, Inc. expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of UCERIS, being developed for the treatment of induction of remission of mild to moderate active ulcerative colitis.
Santarus, Inc. is a specialty biopharmaceutica
August 06-08, 2012 · The Westin San Francisco Market Street · San Francisco, CA
A new paradigm in drug and diagnostic development is emerging. Exciting scientific discoveries in genome biology and technology are paving the way to new product development and commercial opport